News

Baltic biotech attracts investors
Enlarge image

BusinessLithuaniaLatviaEstoniaDenmarkGermanySweden

Baltic biotech attracts investors

17.09.2012 - The very first Life Science Baltics 2012 attracted twice as many visitors than anticipated. Investors are lured by EU funds, low cost and qualified staff.

The very first Life Science Baltics conference almost 800 life science professionals visiting Vilnius. „That’s almost twice than we expected“, Jelena Suchodumceva, Senior Project Manager at Enterprise Lithuania, told EuroBiotechNews at the conference. According to the organisers from the governmental agency, more than 80% of the attendants came from non-Baltic states such as Israel, Canada, the US or EU member states. A trade fair showcasing the offerings of more than 40 companies and over 100 pre-scheduled B2B meetings reflected the huge interest to invest in the Baltic scene.

At the conference, ThermoFisher Scientific stated it will inaugurate a €16m research and production facility next week on the grounds of former Lithuanian Fermantas AB. Furthermore, Biotechpharma UAB received an €11m cash injection from EU structural funds. The money helped the Lithuanian CMO to build a state-of-the-art biopharmaceutical facility, which will become fully operational next year at Santara Valley, a brand-new life sciences-IT incubator in the country’s capital. The cluster is one of 5 high-tech valleys supported by the Lithuanian government with investments of €400m.

Prof. Dr. Vladas Bumelis, Chairman of Biotechpharma and Lithuanian biotech mastermind, said at the conference that investors are attracted by the strong knowledge base, low cost of goods and the governmental commitment to support the life sciences sector. To become a big fish within the life science scene, however, it would be essential for the many but small firms in the Baltic region to swim in formation. According to Enterprise Lithuania, the country’s life sciences industry has been skyrocketing over the last two decades with an annual growth rate of 22%, and over 80% of the production being exported. Last year, exports from the life sciences sector amounted to €276.2m. Its main export markets were Sweden (21.1% of the total); Germany (10.9%); Italy (8.1%); UK (6.%); Denmark (6.7%); Russia (4.7%); Norway (4.6%); Poland (4.3%); France (4%); and Latvia (2.7%).

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2012-03/baltic-biotech-attracts-investors.html

PoliticsEUPolandItalySpainUK

16.12.2014 Two consortia combined of 144 European companies, research institutes and universities have been selected for funding by the EIT in the areas of health and raw materials. Both clusters are set to acquire €1.1bn over the next seven years.

M&ALuxembourg

11.12.2014 Luxembourg bio-analytical testing company Eurofins Scientific has signed an agreement to acquire Boston Heart Diagnostics Corp. for an initial €112m.

StudySwitzerlandEU

10.12.2014 When it comes to the biggest investors in Research and Development (R&D) Swiss pharma top dogs Novartis and Roche have defended their positioning among the top ten companies worldwide – according to a recently published EU study.

FinancingUKSpain

09.12.2014 British drug delivery specialist Midatech Pharma plc floated on the London stock market. It is the third biotech IPO on the AIM market this year.

CooperationAustria

05.12.2014 Austrian contract research company VTU has entered into a development and commercialisation agreement with US company RCT. The partners want to combine both companies' Pichia pastoris protein production technologies under VTU's roof.

FinancingDenmark

03.12.2014 Danish biotech pharma Ascendis has successfully completed a €48m Series D financing round. The funding is expected to support its late-stage clinical trials to push its lead drug into Phase III trials.

RegulationUKFranceGermanySpain

01.12.2014 In spite of innovative new medicines on the market, the UK and Germany lag behind other countries and continue to use older medicines - especially in the treatment of cancer. French and Spanish patients, on the other hand, benefit much earlier from medical innovation.

RegulationItalyGermanyNetherlandsEU

28.11.2014 The first gene therapy for a rare genetic condition — UniQure's Glybera — is on its way to the European market. But there is a hefty price tag: Chiesi, responsible for the marketing of the orphan drug, is asking for a record price of €1.1m per patient.

Events

All Events

Current issue

All issues

Product of the week

Products